MedTrace Logo

A Study of LY3526318 in Healthy Male Japanese Participants

NCT05580250 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2023-01-09

No results posted yet for this study

Summary

This is a study of LY3526318 in healthy male Japanese. The main purposes of this study are to:

* Assess how safe and well tolerated LY3526318 is when given by mouth.
* Measure how LY3526318 affects the kidney and the liver. The study will be conducted in three parts (Part A, Part B, Part C). Participants may only enroll in one part. After screening, the study will last from one to two weeks, depending on part.

Conditions

  • Healthy

Interventions

DRUG

LY3526318

Administered orally.

DRUG

Placebo

Administered orally.

DRUG

Iohexol

Administered intravenously (IV).

DRUG

Simvastatin

Administered orally.

DRUG

Metformin

Administered orally.

Sponsors & Collaborators

Principal Investigators

  • 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-22
Primary Completion
2022-12-08
Completion
2022-12-08

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05580250 on ClinicalTrials.gov